Eli Lilly Sues Compounders Over Unauthorized Copies of Weight-Loss Drugs
Eli Lilly has taken another firm legal stance against compounding pharmacies producing unapproved versions of its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound (tirzepatide). On April 1, 2025, the pharmaceutical giant filed lawsuits against two...
Compounding Pharmacies Fight Back: Fifth Circuit Appeal Filed Over Tirzepatide Injunction Denial
In a significant development within the pharmaceutical compounding industry, the Outsourcing Facilities Association (OFA) has filed an interlocutory appeal to the Fifth Circuit Court of Appeals. This action challenges a recent decision by a federal judge to deny...
Texas Introduces New Bill Targeting Med Spas: House Bill 3749
The Texas legislature is taking a closer look at the med spa industry with the introduction of House Bill 3749, proposed by Representative Angelia Orr on March 4, 2025. This bill is a direct response to growing concerns over patient safety in medical spas,...
Court Ruling Backs FDA, Blocks Compounded Versions of Eli Lilly’s Weight-Loss Drug
In a recent legal development, a U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to continue producing copies of Eli Lilly’s weight-loss medication, Zepbound. This decision stems from an October lawsuit filed by a...